ADCT provided insight into its ADC platform and solid tumor pipeline. The company discussed the broad applicability of its ADC technology and provided a deep dive on its programs including clinical assets Cami, ADCT-901, and ADCT-601.
ImmunoGen and Lilly announced a global licensing agreement to develop ADCs directed to targets selected by Lilly based on ImmunoGen's novel camptothecin technology. ImmunoGen is eligible to receive $13 million upfront and up to $1.7 billion in milestones.
Mersana announced a research collaboration and license agreement with Janssen to discover novel ADCs for three targets. Mersana will receive an upfront payment of $40 million and is eligible to receive more than $1 billion in milestone payments,
Seagen and Astellas announced the initial results from Cohort H of EV-103 trial investigating Padcev (enfortumab vedotin-ejfv) as a monotherapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. Results from the preliminary analysis of 22 patients showed 36.4% had a pathologic complete response, displaying no signs of cancer upon microscopic examination of tissue cells removed during surgery.
Alkermes presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa in RCC patients. The trial included 27 patients with advanced RCC, 56% of whom were CPI-pretreated. Nemvaleukin monotherapy induced robust expansion of CD8+ T and NK cells, with minimal effect on Tregs. Among 23 evaluable patients, four patients achieved a partial response and three of these patients continued on monotherapy.
ImmunityBio announced over 24 months median duration of complete remission with 100% non-muscle invasive bladder cancer patients’ survival. Results confirm prolonged sustained complete response with 71% of patients having a complete remission with a median duration of response of 24.1 months
Nektar announced quarterly loss of $146 million, or $0.79 per share, vs the estimate of loss of $0.81. This compares to loss of $117 million, or $0.65 per share, a year ago.
Xencor announced net income for the fourth quarter was $73 million, or $1.21 on a fully diluted per share basis, compared to a net loss of $14 million, or $0.24 per share, for the same period in 2020. For the full year 2021, net income was $83 million.
Allogene reported net loss for the fourth quarter of 2021 was $75 million, or $0.54 per share. For the full year of 2021, net loss was $257 million, or $1.89 per share.
The short interest of Autolus increased in February by 13 % to 3,075,477 on February 15, compared to 2,719,263 on January 14.
The short interest of Bellicum decreased in February by 35 % to 257,826 on February 15, compared to 395,415 on January 14.
Mustang announced that City of Hope presented Phase 1 trial data on MB-105, a PSCA CAR T-cell therapy, in PSCA-positive mCRPC patients at ASCO GU. The results indicate that the therapy is feasible in patients with mCRPC with DLT of cystitis and show preliminary anti-tumor effect at a dose of 100M cells plus lymphodepletion.
Arcus reported net income of $279 million for fourth quarter, compared to net loss of $52 million for the same period in the prior year. Net income was primarily due to license revenue recognized upon closing of Gilead's exercise in December 2021 of its options. Net income was $53 million for the full year.
Immutep announced it will present new data from the Phase 2 TACTI-002 study of efti at ESMO’s European Lung Cancer Congress. The new data relates to trial evaluating efti in combination with Keytruda in patients with PD-L1 unselected second line PD-1/PD-L1 refractory metastatic NSCLC patients.
Clovis highlighted ongoing Phase 1/2 LuMIERE study and multi-tumor imaging trial of FAP-2286 targeted radiotherapy candidate at Nuclear Medicine meeting. FAP-2286 is the first peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein to enter clinical development.